Sumitomo Dainippon Pharma Co Ltd's Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Ebit" stands at 123.06 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 09/30/2022.
Sumitomo Dainippon Pharma Co Ltd's second quarter result of 80.87 Billion JPY for the item "Ebit" represents an increase of 285.37 percent compared to it's first quarter result.
Also, Sumitomo Dainippon Pharma Co Ltd's second quarter result of 80.87 Billion JPY for the item "Ebit" represents an increase of 408.65 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sumitomo Dainippon Pharma Co Ltd's second quarter result of 123.06 Billion JPY for the item "Ebit" represents an increase of 669.78 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 377.66 Billion Japanese Yens compared to the value the year prior.
The 1 year change is 377.66 Billion Japanese Yens.
The 3 year change is 65.04 Billion Japanese Yens.
The 5 year change is 58.14 Billion Japanese Yens.
The 10 year change is 86.88 Billion Japanese Yens.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Ebit | 905,699,262,464.00 |
![]() | Johnson & Johnson - Ebit | 486,508,953,600.00 |
![]() | AbbVie Inc - Ebit | 399,570,305,024.00 |
![]() | Roche Holding AG - Ebit | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Ebit | 280,205,508,085.11 |